TD Cowen Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $23.00

Hims & Hers Health (NYSE:HIMS) had its price objective lowered by equities research analysts at TD Cowen from $25.00 to $23.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen’s price objective indicates a potential upside of 16.02% from the stock’s current price.

A number of other equities analysts have also recently weighed in on HIMS. Leerink Partners upped their price objective on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Barclays lifted their price objective on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. Finally, Truist Financial reiterated a “hold” rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $31.71.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $1.04 on Friday, reaching $19.83. 7,347,645 shares of the company’s stock traded hands, compared to its average volume of 34,211,336. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of 38.90, a P/E/G ratio of 2.41 and a beta of 2.55. The stock has a 50 day moving average price of $21.97 and a 200-day moving average price of $36.08.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the company earned $0.11 EPS. Equities research analysts predict that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 9,217 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09. Following the completion of the transaction, the chief financial officer owned 318,789 shares of the company’s stock, valued at approximately $7,577,614.53. This trade represents a 2.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael Chi sold 97,289 shares of Hims & Hers Health stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 134,984 shares of company stock valued at $3,458,041. 13.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently modified their holdings of the stock. Pathway Capital Management LP acquired a new position in shares of Hims & Hers Health during the third quarter worth about $6,766,000. Steadview Capital Management LLC lifted its stake in Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after acquiring an additional 311,845 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. State of Michigan Retirement System raised its holdings in shares of Hims & Hers Health by 49.2% in the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock valued at $116,713,000 after purchasing an additional 678,600 shares in the last quarter. Finally, BIT Capital GmbH lifted its position in shares of Hims & Hers Health by 73.8% during the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after purchasing an additional 938,728 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims announced availability of a broad lineup of Novo Nordisk FDA‑approved GLP‑1s (including Wegovy® and Ozempic) to eligible customers, expanding HIMS’s addressable market, product mix and potential ARPU upside. Read More.
• Positive Sentiment: Market commentary and analyst writeups argue the Novo settlement removed a key legal overhang and clears the path to sell branded drugs — a structural catalyst for revenue and margin improvement. Read More.
• Positive Sentiment: Recent earnings momentum (an EPS beat and strong subscriber/revenue growth) has driven a multi‑week rally, supporting the view that fundamentals are improving after the litigation resolution. Read More.
• Neutral Sentiment: Coverage highlights a strategic shift toward a broader branded GLP‑1 and telehealth mix following the Novo deal — potentially positive long‑term but execution‑dependent in the near term. Read More.
• Neutral Sentiment: Marketing and sponsored features position the brand in consumer channels (helpful for awareness) but are not immediate earnings drivers. Read More.
• Negative Sentiment: An analyst price target was cut (reported ~14.6% lower), which lowers street expectations and can prompt profit‑taking after the recent run. Read More.
• Negative Sentiment: Shareholder litigation: the Schall Law Firm opened a securities‑fraud investigation into HIMS, adding legal/regulatory risk that can keep sentiment subdued until resolved. Read More.
• Negative Sentiment: Insider selling: the CFO disclosed a ~9.2k‑share sale in March, and persistent insider dispositions have been cited as a sentiment headwind. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.